Not by design, but it looks like actual trial completion on the primary endpoint will be resolved post election. If successful, NWBO may be one of the first companies to negotiate price directly with Medicare. In Europe, they would of course need to receive price approval from NICE.
This may sound unimportant, but my guess is that Medicare will soon have the same authority as NICE to regulate drug prices through reimbursement leverage.
Elections have consequences, and I see NWBO getting in on the ground floor out of the gate (perhaps even voluntarily before the law is changed) if approved, whereas companies with drugs already on the market may be looking at profit reduction regarding some medicines, particularly where they are scrutinized more closely for actual benefit. Hint: Both candidates want the law changed to allow Medicare to directly negotiate prescription drug prices. http://healthaffairs.org/blog/2016/09/19/the-politics-of-medicare-and-drug-price-negotiation/